Optiscan Submitted Devices for FDA Cancer Surgery Review
New imaging tools could allow surgeons to view cancer cells in real time during operations.
Updated on Oct. 4, 2026 in Cancer
Live Poll
Do you trust that new medical imaging technologies generally lead to better patient outcomes?
Optiscan has submitted 510(k) applications to the U.S. FDA for its InVue precision surgery device and its InForm digital pathology device. These technologies aim to assist in cancer procedures, which represent a significant portion of patient care in the U.S.
Why it matters
With approximately 60% of cancer patients undergoing surgery, real-time cellular imaging could change how surgeons identify and remove tissue. These submissions mark a step toward integrating high-resolution digital tools into the standard operating room environment.
Optiscan submitted its InVue and InForm devices for regulatory review to support intraoperative imaging capabilities. While these tools target a market segment valued at US$4.8 billion annually, their efficacy in reducing cancer recurrence remains under investigation.
The players
Optiscan
A medical technology company focused on developing digital pathology and real-time intraoperative imaging solutions.
FDA
The federal agency responsible for evaluating the safety and effectiveness of medical devices before they enter the U.S. market.
The details
The InVue device is designed to provide surgeons with the ability to visualize tissue at a cellular level in real time during procedures. By enabling this level of micro-imaging, the technology seeks to improve surgical precision. The FDA review process will assess the technical, performance, and clinical evidence provided to ensure these devices meet safety and efficacy standards for use in clinical settings.
Timeline
Optiscan unveiled the InVue device in June 2024.
The InForm device application was submitted for FDA review on October 2, 2026.
Health Landscape
These applications reflect a broader push to modernize surgical oncology through advanced digital visualization tools. The sector is currently tracking toward an intraoperative imaging market size of US$1.55 billion by 2030.
If you or a family member are preparing for cancer-related surgery, it is worth asking a surgeon about the imaging technologies they use to guide their work. Discussions regarding new surgical tools should always be directed to your surgical team to understand current standards of care.
The takeaway
Advancements in intraoperative imaging aim to provide surgeons with clearer, real-time views of tissue during cancer procedures. When meeting with an oncology team, consider asking how new imaging technologies might support the planning and execution of your surgery.
Further reading
For more developments in surgical oncology and medical innovations, explore our Cancer section.
Live Poll
Do you trust that new medical imaging technologies generally lead to better patient outcomes?
